Evidence map›Paper›PMID 21538388›Full record

Trial reportClinical cardiology2011

Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.

Claudius Jacobshagen, Luiz Belardinelli, Gerd Hasenfuss, Lars S Maier

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2017
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Pre-clinical diastolic dysfunction.Journal of the American College of Cardiology · 2014
    Review
  14. Update on heart failure with preserved ejection fraction.Current cardiovascular risk reports · 2013
    Article
  15. Positioning of inflammatory biomarkers in the heart failure landscape.Journal of cardiovascular translational research · 2013
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Claudius JacobshagenDepartment of Cardiology and Pneumology, Georg-August-University, Robert-Koch-Strasse 40, Göttingen, Germany.
Luiz Belardinelli
Gerd Hasenfuss
Lars S Maier
University of Göttingen · DEGilead Sciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart failure with preserved ejection fraction (HFpEF), formerly referred to as diastolic heart failure (DHF), accounts for >50% of all HF patients. So far, there has been no specific treatment for impaired left ventricular (LV) relaxation. Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. HYPOTHESIS: RAnoLazIne for the Treatment of Diastolic Heart Failure (RALI-DHF) is a prospective, single-center, randomized, double-blind, placebo-controlled proof-of-concept study to determine if ranolazine compared with placebo will be more effective in improving diastolic function in patients with HFpEF.

methodsTwenty patients with HFpEF (EF ≥ 50% and ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity [E/E'] >15 or N-terminal pro-type brain natriuretic peptide >220 pg/mL) will be randomized to receive ranolazine or placebo in a 1.5:1 ratio during their catheterization if the LV end-diastolic pressure is ≥18 mm Hg and the time constant of relaxation (τ) is ≥50 ms. Treatment will consist of intravenous infusion of study drug (or placebo) for 24 hours, followed by oral treatment for a total of 14 days. ENDPOINTS: The study will include the following exploratory endpoints: (1) change from baseline to 30 minutes from initiation of intravenous study drug administration during cardiac catheterization hemodynamic parameters at both resting and paced (120 beats per minute) conditions: τ, LV end-diastolic pressure, and dP/dt(min) .; and (2) change from baseline to day 14 in E/E', maximal oxygen consumption, and N-terminal pro-type brain natriuretic peptide.

conclusionsThe RALI-DHF study is designed as a translational study to bridge the gap between basic science and therapeutics and to determine if ranolazine, compared with placebo, will be more effective in improving diastolic function in patients with HFpEF.

Indexed as

Research DesignStroke VolumeAcetanilidesAdministration, OralBiomarkersCardiac CatheterizationCardiovascular AgentsDouble-Blind MethodEchocardiography, DopplerGermanyHeart Failure, DiastolicHumansInfusions, IntravenousNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsAcetanilidesBiomarkersCardiovascular AgentsNatriuretic Peptide, BrainPeptide FragmentsPiperazinespro-brain natriuretic peptide (1-76)Ranolazine

Identifiers

PMID21538388
PMCPMC6652542
OpenAlexW2051086204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.